Gyermekkori daganatok: vizsgálatok itt: Dél-Korea
64 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- No phaseTaking peopleProspective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV
- Where
- Seoul
- People
- 2000
- Run by
- Samsung Medical Center
See details and how to joinNCT07032103 - 1/2. fázisTaking peopleStudy to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
- Where
- Gyeonggi-do, Seoul
- Életkor
- 12 év and over
- People
- 78 worldwide
- Run by
- MedPacto, Inc.
See details and how to joinNCT05588648 - 2/3. fázisTaking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Daegu, Seoul
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - 1/2. fázisTaking peopleA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Seoul
- Életkor
- 1 hónap to 17 év
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00 - No phaseTaking peopleImjudo & Imfinzi PMS
- Where
- Busan, Goyang, Seongnam, Seoul, Suwon
- People
- 246
- Run by
- AstraZeneca
See details and how to joinNCT06544629 - 1. fázisTaking peopleA Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Where
- Seoul
- Életkor
- 6 hónap to 17 év
- People
- 18 worldwide
- Run by
- AbbVie
See details and how to joinNCT07306832 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - No phaseNot yet taking people in Dél-KoreaRepotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 10
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07599007 - 1/2. fázisTaking peopleA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Where
- Seoul
- Életkor
- Up to 25 év
- People
- 75 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00 - 1/2. fázisTaking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Gyeonggi-do, Seoul
- Életkor
- 12 év and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - 3. fázisTaking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Seoul
- Életkor
- 12 év to 100 év
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - No phaseTaking peopleDurvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
- Where
- Seoul
- People
- 50
- Run by
- AstraZeneca
See details and how to joinNCT06995833 - No phaseTaking peopleReal-World Treatment Study of Koselugo (Selumetinib)
- Where
- Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju, Yangsan
- Életkor
- 3 év to 99 év
- People
- 200
- Run by
- AstraZeneca
See details and how to joinNCT06360406 - 2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 100 worldwide
- Run by
- AbbVie
See details and how to joinNCT07196644 · EU 2024-518871-74-00 - No phaseTaking peopleLong-term Follow up Local Registry Study of Kymriah in South Korea
- Where
- Bundang Gu, Busan, Gyeonggi-do, Incheon, Jeollanam, Seongnam-si, Seoul, Ulsan
- Életkor
- 0 év to 100 év
- People
- 500
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06785818 - 2. fázisTaking peopleEvaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
- Életkor
- 1 év to 22 év
- People
- 90
- Run by
- Ho Joon Im
See details and how to joinNCT05827549 - 2. fázisTaking peopleTreatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Seoul, Suwon, Yangsan
- Életkor
- 1 év to 9 év
- People
- 116
- Run by
- Hee Young Ju
See details and how to joinNCT06099366 - 2. fázisTaking peopleTreatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
- Where
- Incheon, Seoul, Suwon, Yangsan
- Életkor
- 1 év to 19 év
- People
- 370
- Run by
- Jae Wook Lee
See details and how to joinNCT06184009 - 2. fázisTaking peopleTreatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
- Életkor
- 1 év to 19 év
- People
- 74
- Run by
- Hyoung Jin Kang
See details and how to joinNCT06257394 - 2. fázisTaking peopleEfficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Pusan, Seoul
- Életkor
- Up to 2 év
- People
- 40
- Run by
- Yonsei University
See details and how to joinNCT06516679 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Hwasun, Pusan, Seoul, Suwon
- Életkor
- 8 év and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - 1/2. fázisTaking peopleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Cheongju-si, Hwasun-eup, Hwasun-gun, Seoul
- Életkor
- 12 év and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - 3. fázisTaking peopleONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
- Where
- Bundang-gu, Seongnam-si, Bundang-Gu, Seongnam-Si, Gangnam, Gangnam-Gu, Ilsandong-gu, Goyang-si, Jongno-gu, Seoul
- People
- 510 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT05580562 · EU 2022-502051-56-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Hwasun, Seoul
- Életkor
- 12 év and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555 - No phaseNot yet taking people in Dél-KoreaProspective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
- Where
- Seoul
- People
- 600
- Run by
- Asan Medical Center
See details and how to joinNCT07382505